Dolutegravir--a promising antiretroviral in development.
University of New South Wales, The Kirby Institute for infection and immunity in society, 45 Beach Street, Coogee, NSW 2034, Australia. mboyd@nchecr.unsw.edu.au
Mark
M
Boyd
D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000502:physiology*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir
D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir